Medical Research Council, stated that in regards to the MRC=92s recent
=A31.6m funding initiative for biomedical research into M.E., "One of
the studies plans to use an existing cohort of patients to get a
molecular handle on a finger print of fatigue. Within that study is a
small group of patients who are being trialled with Rituximab, so this
study seeks to compare and contrast symptoms with a known study."*
According to the recent study announcements, the 'molecular
fingerprint of fatigue' study is the one that is set to include
patients with Sjogren's syndrome. I have made further inquiries as to
whether the small trial of Rituximab was to include ME/CFS patients
and was told it would not, despite ME/CFS patients taking part in the
larger study. So apparently the MRC is planning on using ring-fenced
monies specifically earmarked for research into ME/CFS and spending it
on a trial on Rituximab in Sjogren's syndrome patients. Seeing as how
the recent Rituximab findings have the potential to be one of the
biggest breakthroughs in the history of ME/CFS research, would it not
be appropriate to include ME/CFS patients in this trial as well?
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Too much mail? Try a digest version. See http://www.co-cure.org/digest.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
